@article{CJCR6480,
author = {Lin Li and Zijin Zhang and Zhixin Bie and Zheng Wang and Ping Zhang and Xin Nie and Yuanming Li and Hui Wang and Bin Ai and Gang Cheng},
title = {Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients},
journal = {Chinese Journal of Cancer Research},
volume = {27},
number = {3},
year = {2015},
keywords = {},
abstract = {Background: Epidermal growth factor receptor (EGFR) mutation is the key predictor of EGFR tyrosine kinase inhibitors (TKIs) efficacy in non-small cell lung cancer (NSCLC). We conducted this study to verify the feasibility of EGFR mutation analysis in cytological specimens and investigate the responsiveness to gefitinib treatment in patients carrying EGFR mutations.
Methods: A total of 210 cytological specimens were collected for EGFR mutation detection by both direct sequencing and amplification refractory mutation system (ARMS). We analyzed EGFR mutation status by both methods and evaluated the responsiveness to gefitinib treatment in patients harboring EGFR mutations by overall response rate (ORR), disease control rate (DCR) and progression free survival (PFS).
Results: Of all patients, EGFR mutation rate was 28.6% (60/210) by direct sequencing and 45.2% (95/210) by ARMS (P},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/6480}
}